

Organic Technologies Posts Positive Business Outlook Based on Expanding Product Mix



Organic Technologies begins 2013 with an expanding product mix and planned capacity increases. The Coshocton, OH-based fine chemicals producer and custom manufacturer comes to Informex with a positive business outlook and an interest in featuring new product growth areas.

The privately held firm, formerly known in the industry as Wiley Organics, has grown beyond its historical catalog business and now focuses on four key areas: food and nutritional ingredients, fine chemicals and specialty gas components, toll distillation and custom manufacturing.

CEO and President David B. Wiley noted that Organic Technologies' diversity of product mix is unusual but purposeful: "As a company with experience in both synthetic chemistry and separations, we saw a unique opportunity to produce a fully American sourced and manufactured omega-3 product to the highest purity and quality standards. This was made possible by our experience in high efficiency distillation and other purification techniques."

In fiscal year 2012, sales revenue hit a record level and employment increased by about 12 percent, as validation of the company's strategy.

The functional food area has been accompanied by growth in the fine chemicals and specialty gas components business. Jack Etheridge, VP, cited three specific developments: "First, we have been able to step in and supply some products no longer

supplied by larger firms. Secondly, we are producing higher purity items, especially specialty gas components. Thirdly, we are increasing our scale of production of certain acetylenics, such as 1-butyne." Visit Organic Technologies at Booth 1247 . □

PharmaCore's In-House Analytical Chemistry Department Supports Scale-Up Projects

PharmaCore GMP Analytical believes that it is critical to focus on supporting projects from the ground up. PharmaCore's team of analytical scientists interfaces directly with scientists and process chemists from the start of each project.

From testing incoming raw materials against strictly controlled standards, through in-process and intermediate testing support, to GMP release of final product—and beyond, to qualification of Reference Standards and in-house support to ICH Stability Studies—PharmaCore's GMP analytical laboratory provides support to all projects.

With more than 100 years of combined pharmaceutical experience, the lab now employs six full-time analytical chemists and supports all phases of in-house contract API production from eight separate production suites. The recently expanded 40,000 sq. ft. facility has the capability to produce 50+ Kg batch sizes for materials in phases up to and including Phase 3.

PharmaCore's pharmaceutical analytical services also are available on a contract basis. In this vein, PharmaCore's GMP analytical laboratory focuses on the API arena and provides expertise in and support for: analytical methods development, validation (including Residual Solvents), and transfer; cleaning validation; and consultation

Visit PharmaCore at Booth 1508 . □



New Cytotoxic Plant:

Helsinn Advanced Synthesis S.A. has started the activities in the New Cytotoxic Plant.

manufacturing@helsinn.com

Tel. +41 (0) 91 873. 94. 00

Visit Informex 2013, Anaheim
February 19-22, Booth #1809 (Hall C)

HELINN

Shaping alliances, building pharmaceuticals

The Art of Cytotoxic Manufacturing

Helsinn Advanced Synthesis S.A., Biasca, Switzerland offers its partners **up-to-date technologies and the highest quality standards** for manufacturing APIs, HPAPIs and now Cytotoxic compounds.

Through its Chemical Know-how, R&D expertise and solid CMC approach Helsinn is the right partner from the **development**, through **registration, validation and commercial manufacturing**.

